These results indicate that CDK2 and CDK4/6 targeting induced by abemaciclib is less efficient than the triple combination in resistant ER+ BC cells expressing high CDK6, p-CDK2, and/or cyclin E1. Here, CCNE1 is linked to breast cancer.